JAMA (Journal of the American Medical Association)
الذهاب إلى القناة على Telegram
All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
إظهار المزيد📈 نظرة تحليلية على قناة تيليجرام JAMA (Journal of the American Medical Association)
تُعد قناة JAMA (Journal of the American Medical Association) (@jamaupdates) في القطاع اللغوي الإنكليزية لاعباً نشطاً. يضم المجتمع حالياً 16 180 مشتركاً، محتلاً المرتبة 1 487 في فئة الطب والمرتبة 2 317 في منطقة الولايات المتحدة.
📊 مؤشرات الجمهور والحراك
منذ تأسيسه في невідомо، حقق المشروع نمواً سريعاً وجمع 16 180 مشتركاً.
بحسب آخر البيانات بتاريخ 26 أغسطس, 2026، تحافظ القناة على نشاط مستقر. خلال آخر 30 يوماً تغيّر عدد الأعضاء بمقدار 346، وفي آخر 24 ساعة بمقدار 16، مع بقاء الوصول العام مرتفعاً.
- حالة التحقق: غير موثّقة
- معدل التفاعل (ER): يبلغ متوسط تفاعل الجمهور 4.36%. وخلال أول 24 ساعة من النشر يحصد المحتوى عادةً 2.06% من ردود الفعل نسبةً إلى إجمالي المشتركين.
- وصول المنشورات: يحصل كل منشور على متوسط 705 مشاهدة. وخلال اليوم الأول يجمع عادةً 334 مشاهدة.
- التفاعلات والاستجابة: يتفاعل الجمهور بانتظام؛ متوسط التفاعلات لكل منشور يبلغ 1.
- الاهتمامات الموضوعية: يركز المحتوى على مواضيع رئيسية مثل patient, disease, treatment, drug, guideline.
📝 الوصف وسياسة المحتوى
يصف المؤلف القناة بأنها مساحة للتعبير عن الآراء الذاتية:
“All the latest articles published on JAMA before going in to print
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
بفضل وتيرة التحديث المرتفعة (أحدث البيانات بتاريخ 27 أغسطس, 2026) تحافظ القناة على حداثتها ومستوى وصول مرتفع. وتُظهر التحليلات تفاعلاً نشطاً من الجمهور، ما يجعلها نقطة تأثير مهمة ضمن فئة الطب.
16 180
المشتركون
+1624 ساعات
+857 أيام
+34630 أيام
جاري تحميل البيانات...
القنوات المماثلة
سحابة العلامات
الإشارات الواردة والصادرة
---
---
---
---
---
---
جذب المشتركين
أغسطس '26
أغسطس '26
+314
في 0 قنوات
يوليو '26
+440
في 0 قنوات
Get PRO
يونيو '26
+422
في 0 قنوات
Get PRO
مايو '26
+584
في 0 قنوات
Get PRO
أبريل '26
+437
في 0 قنوات
Get PRO
مارس '26
+217
في 0 قنوات
Get PRO
فبراير '26
+247
في 0 قنوات
Get PRO
يناير '26
+321
في 0 قنوات
Get PRO
ديسمبر '25
+277
في 0 قنوات
Get PRO
نوفمبر '25
+366
في 2 قنوات
Get PRO
أكتوبر '25
+164
في 0 قنوات
Get PRO
سبتمبر '25
+12
في 0 قنوات
Get PRO
أغسطس '25
+29
في 0 قنوات
Get PRO
يوليو '25
+30
في 0 قنوات
Get PRO
يونيو '25
+17
في 0 قنوات
Get PRO
مايو '25
+9
في 0 قنوات
Get PRO
أبريل '25
+5
في 0 قنوات
Get PRO
مارس '25
+17
في 0 قنوات
Get PRO
فبراير '25
+12
في 0 قنوات
Get PRO
يناير '25
+18
في 1 قنوات
Get PRO
ديسمبر '24
+237
في 0 قنوات
Get PRO
نوفمبر '24
+1 122
في 0 قنوات
Get PRO
أكتوبر '24
+1 120
في 0 قنوات
Get PRO
سبتمبر '24
+1 527
في 1 قنوات
Get PRO
أغسطس '24
+1 128
في 1 قنوات
Get PRO
يوليو '24
+1 216
في 0 قنوات
Get PRO
يونيو '24
+781
في 1 قنوات
Get PRO
مايو '24
+797
في 1 قنوات
Get PRO
أبريل '24
+808
في 1 قنوات
Get PRO
مارس '24
+821
في 2 قنوات
Get PRO
فبراير '24
+753
في 1 قنوات
Get PRO
يناير '24
+768
في 0 قنوات
Get PRO
ديسمبر '23
+716
في 1 قنوات
Get PRO
نوفمبر '23
+96
في 1 قنوات
Get PRO
أكتوبر '23
+86
في 0 قنوات
Get PRO
سبتمبر '23
+73
في 0 قنوات
Get PRO
أغسطس '23
+90
في 0 قنوات
Get PRO
يوليو '23
+107
في 0 قنوات
Get PRO
يونيو '23
+105
في 0 قنوات
Get PRO
مايو '23
+169
في 0 قنوات
Get PRO
أبريل '23
+128
في 0 قنوات
Get PRO
مارس '23
+84
في 0 قنوات
Get PRO
فبراير '23
+75
في 0 قنوات
Get PRO
يناير '23
+71
في 0 قنوات
Get PRO
ديسمبر '22
+74
في 0 قنوات
Get PRO
نوفمبر '22
+149
في 0 قنوات
Get PRO
أكتوبر '22
+90
في 0 قنوات
Get PRO
سبتمبر '22
+138
في 0 قنوات
Get PRO
أغسطس '22
+77
في 0 قنوات
Get PRO
يوليو '22
+50
في 0 قنوات
Get PRO
يونيو '22
+96
في 0 قنوات
Get PRO
مايو '22
+75
في 0 قنوات
Get PRO
أبريل '22
+80
في 0 قنوات
Get PRO
مارس '22
+65
في 0 قنوات
Get PRO
فبراير '22
+26
في 0 قنوات
Get PRO
يناير '22
+56
في 0 قنوات
Get PRO
ديسمبر '21
+44
في 0 قنوات
Get PRO
نوفمبر '21
+39
في 0 قنوات
Get PRO
أكتوبر '21
+61
في 0 قنوات
Get PRO
سبتمبر '21
+66
في 0 قنوات
Get PRO
أغسطس '21
+65
في 0 قنوات
Get PRO
يوليو '21
+96
في 0 قنوات
Get PRO
يونيو '21
+120
في 0 قنوات
Get PRO
مايو '21
+130
في 0 قنوات
Get PRO
أبريل '21
+812
في 0 قنوات
| التاريخ | نمو المشتركين | الإشارات | القنوات | |
| 27 أغسطس | +5 | |||
| 26 أغسطس | +16 | |||
| 25 أغسطس | +3 | |||
| 24 أغسطس | +7 | |||
| 23 أغسطس | +9 | |||
| 22 أغسطس | +12 | |||
| 21 أغسطس | +24 | |||
| 20 أغسطس | +15 | |||
| 19 أغسطس | +11 | |||
| 18 أغسطس | +10 | |||
| 17 أغسطس | +17 | |||
| 16 أغسطس | +7 | |||
| 15 أغسطس | +14 | |||
| 14 أغسطس | +14 | |||
| 13 أغسطس | +9 | |||
| 12 أغسطس | +14 | |||
| 11 أغسطس | +19 | |||
| 10 أغسطس | +7 | |||
| 09 أغسطس | +15 | |||
| 08 أغسطس | +18 | |||
| 07 أغسطس | +2 | |||
| 06 أغسطس | +16 | |||
| 05 أغسطس | +5 | |||
| 04 أغسطس | +13 | |||
| 03 أغسطس | +11 | |||
| 02 أغسطس | +9 | |||
| 01 أغسطس | +12 |
منشورات القناة
Amoxicillin-Clavulanate vs Amoxicillin for Sinusitis
https://jamanetwork.com/journals/jama/fullarticle/2853349
To the Editor Dr Savage and colleagues reported no difference in treatment failure between standard-dose amoxicillin-clavulanate and amoxicillin among adults aged 18 to 64 years treated for outpatient acute sinusitis, whereas amoxicillin-clavulanate was associated with higher risks of yeast infection and Clostridioides difficile infection. These findings are important for antimicrobial stewardship and support narrower-spectrum therapy when antibiotics are indicated for uncomplicated acute sinusitis.
| 2 | Amoxicillin-Clavulanate vs Amoxicillin for Sinusitis
https://jamanetwork.com/journals/jama/fullarticle/2853350
To the Editor The retrospective cohort study by Dr Savage and colleagues compared outcomes of narrow- vs broader-spectrum antibiotics for acute sinusitis. Although the authors’ findings support use of amoxicillin when antibiotics are prescribed, the underlying assumption that most patients truly had acute bacterial sinusitis warrants closer scrutiny. | 382 |
| 3 | Cannabinoid Hyperemesis Syndrome
https://jamanetwork.com/journals/jama/fullarticle/2853351
This JAMA Insights discusses cannabinoid hyperemesis syndrome, including pathophysiology, clinical presentation, and the epidemiology and risk factors. | 339 |
| 4 | Revised Supplement 2
https://jamanetwork.com/journals/jama/fullarticle/2853352
The Original Investigation titled “Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis,” published on October 3, 2023, was corrected to update Supplement 2. In the original supplement, eTable 21 and eTable 22 were identical and did not have the correct information. This article was corrected online. | 302 |
| 5 | Venous Thromboembolism Risk and Lipid-Lowering Therapy
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853339
To the Editor The post hoc analysis of the CLEAR Outcomes trial by Spiazzi and colleagues provides a clinically stimulating observation: bempedoic acid was associated with a 42% relative reduction in venous thromboembolism (VTE) among statin-intolerant patients at high cardiovascular risk or with established cardiovascular disease. This quantitative signal is particularly relevant because VTE, encompassing deep vein thrombosis and pulmonary embolism, remains a frequent and potentially severe condition, associated with substantial morbidity, mortality, recurrence, and health care burden. | 346 |
| 6 | Bleeding and Stroke Prevention After Left Atrial Appendage Occlusion
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853340
To the Editor Schmidt et al provide informative, long-term data on major bleeding (MB) after left atrial appendage occlusion (LAAO). However, several aspects merit further discussion in the context of the evolving use of LAAO and contemporary postprocedural management. | 278 |
| 7 | Left Atrial Systolic Collapse in Cardiac Tamponade
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853341
This case report discusses cardiac tamponade identified through left atrial collapse in a woman in her late 60s with a history of hypertension and diabetes who presented with progressive dyspnea and chest pain. | 256 |
| 8 | Vutrisiran and Transthyretin Amyloidosis With Cardiomyopathy
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853333
This post hoc analysis of a randomized clinical trial investigates the association of right ventricular (RV) function with clinical outcomes and evaluates the effect of vutrisiran on measures of RV function. | 241 |
| 9 | Inequities in Age-Related Perinatal Cardiometabolic Risk
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853335
This cross-sectional study quantifies disparities in age-related risk of perinatal cardiometabolic conditions at the intersection of race and ethnicity and socioeconomic status. | 237 |
| 10 | Left Atrial Appendage Occlusion vs Oral Anticoagulation—No Free Lunch
https://jamanetwork.com/journals/jamacardiology/fullarticle/2853343
Atrial fibrillation (AF) is a leading cause of ischemic stroke. Moreover, strokes due to AF are more likely to have larger infarct volume, more frequent hemorrhagic transformation, and more severe disability and mortality. Oral anticoagulation (OAC) is recommended in individuals with AF who are at increased risk for stroke. Although OAC is highly effective at reducing the risk of stroke, adherence to OAC is challenging due to the risk of bleeding, adverse effects like bruising, and financial cost. Transesophageal echocardiography and autopsy data suggest that approximately 90% of embolic strokes in individuals with nonrheumatic AF are due to thrombi that originate in the left atrial appendage. Thus, in theory, percutaneous left atrial appendage occlusion (LAAO) should reduce the risk of ischemic stroke and reduce the risk of bleeding if patients can discontinue OAC. Yet as with any procedure, LAAO has risks, including procedural complications, incomplete seal, device-related thrombus, and a need for postprocedural antithrombotic therapy. The 2023 American College of Cardiology (ACC)/American Heart Association (AHA)/American College of Clinical Pharmacy (ACCP)/Heart Rhythm Society (HRS) guidelines state that percutaneous LAAO may be a reasonable alternative to OAC based on patient preference in those with AF who have a high risk of major bleeding (class 2b). | 326 |
| 11 | Affiliations Updated
https://jamanetwork.com/journals/jama/fullarticle/2853317
The Original Investigation titled “Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023,” published July 29, 2026, was corrected to update the author affiliations list. This article was corrected online. | 452 |
| 12 | Health Care Ownership and Patient Care
https://jamanetwork.com/journals/jama/fullarticle/2853252
This Viewpoint discusses how consolidation in frontline care delivery has shaped health care markets across the US and how changes in ownership of hospitals and practices affect clinicians and patient outcomes. | 584 |
| 13 | Postural Orthostatic Tachycardia Syndrome
https://jamanetwork.com/journals/jama/fullarticle/2853253
This review summarizes current evidence on pathophysiology, diagnosis, and management of postural orthostatic tachycardia syndrome (POTS). | 563 |
| 14 | Managing Chronic Subdural Hematoma—Reply
https://jamanetwork.com/journals/jama/fullarticle/2853254
In Reply We thank Dr Madsbu and colleagues for their thoughtful comments regarding our trial and for highlighting the importance of optimizing surgical management in patients with chronic subdural hematoma. | 522 |
| 15 | Managing Chronic Subdural Hematoma
https://jamanetwork.com/journals/jama/fullarticle/2853255
To the Editor Interest in embolization of the middle meningeal artery (EMMA) for chronic subdural hematoma is growing, and the trial by Dr Shankar and colleagues is welcome. The decision to randomize patients to adjuvant embolization after surgical drainage is commendable because it preserves blinding of the surgeon and isolates the effect of embolization from variability in surgical performance. | 454 |
| 16 | Rural-Urban Disparities in the Delivery and Intensity of the Medicare Hospice Benefit
https://jamanetwork.com/journals/jama/fullarticle/2853256
This cross-sectional study examines how hospice care varies across the rural-urban continuum, including length of stay, care setting, visits by hospice staff, and rates of higher-level care. | 381 |
| 17 | Nonreporting of Race and Ethnicity in Medical Research Harms Us All
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852653
At JAMA Internal Medicine, we have become increasingly aware that some US researchers are unable to report on race or ethnicity as demographic variables to describe their sample or to conduct stratified analyses by these variables. In some cases, we have been informed that based on 3 recent US federal executive orders, the stewards of federal databases, such as those responsible for distributing data from the Centers for Medicaid and Medicare Services (CMS), are unable to release any race or ethnicity data for research purposes. The restrictions may be particularly prohibitive when study investigators are US federal employees. We have been informed of similar concerns occurring at other biomedical journals. The potential for restricted access to race and ethnicity data across many federal databases has been highlighted, with disruptions reported during 2025 at the Behavioral Risk Factor Surveillance System (BRFSS) and other Centers for Disease Control and Prevention (CDC) databases, the US Census database, Health and Human Services (HHS), and National Institutes of Health (NIH) public use databases. | 370 |
| 18 | Public Access to NIH-Funded Research Manuscripts
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852654
Health Care Policy | 315 |
| 19 | Error in References
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2852655
The Viewpoint, “Scientific Writing, Generative Artificial Intelligence, and the Non–Native English Speaker,” published in JAMA Internal Medicine online on May 18, 2026, and in the July 2026 issue, included 2 erroneous references. The author has explained that both are genuine sources but that errors were introduced when a generative artificial intelligence tool was used for reformatting references and when the DOI (digital object identifier) of a different version of a conference document was updated manually. The article has been corrected. | 325 |
| 20 | TDP-43–Associated Neurodegenerative Disease
https://jamanetwork.com/journals/jamaneurology/fullarticle/2853086
This narrative review discusses an alternative approach to disease classification based on underlying pathobiology, specifically examining the role of transactive response DNA-binding protein, 43 kDa (TDP-43), pathology in neurodegenerative disorders, paving the way for the development of biomarkers and the advancement of therapeutic candidates that effectively target fundamental disease mechanisms. | 416 |
